ReviewIET nanobiotechnology2025
Enhancing Radiotherapy for Hypoxic Tumors: Integrative Strategies Using Bacteria and Nanoparticles.
Review in IET nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Immunomodulatory effects of ultrasonically lysed Bifidobacterium breve on Pam3CSK4-stimulated J774A.1 macrophages via SIRT1/NRF2 activation and NF-κB suppression.International microbiology : the official journal of the Spanish Society for Microbiology · 2026Article
- SERPINE1 maintained expression by NR4A1 promotes invasion and migration of glioblastoma in hypoxic microenvironment.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer remains a major global health challenge, with radiotherapy (RT) being a cornerstone of treatment. However, the efficacy of RT is significantly hindered by hypoxic tumor microenvironments (TMEs) and nonselective toxicity to healthy tissues. Recent advancements in combining bacteria and nanoparticles have shown promise in addressing these limitations. Cyanobacteria, with their oxygen-producing capabilities, alleviate tumor hypoxia, while anaerobic bacteria selectively target hypoxic regions. Nanoparticles complement these approaches by enhancing bacterial localization and amplifying radiosensitization through reactive oxygen species (ROS) generation and other synergistic therapies. Unlike previous reviews that have mainly focused on either bacterial therapy or nanoparticle-assisted radiosensitization separately, this review provides a comparative and integrative perspective on their combined use, emphasizing the novelty of synergistic strategies. This review explores innovative bacterial-nanoparticle integrations, highlighting their roles in overcoming hypoxia and improving RT outcomes. The potential of these strategies to transform cancer treatment is discussed, alongside challenges and future directions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.